Scheme 1.
Nanoparticle for co-delivery of Selumetinib (SEL) and Osimertinib (OSI) to overcome drug resistance in NSCLC though synergistic effects on mEGFR and MEK.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.